XML 92 R79.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-based Compensation (Restated) - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2024
Share-Based Payment Arrangement      
Percentage increase of issued and outstanding shares   1.00%  
Accrued stock based compensation $ 16,356,000 $ 0  
Change in accrued stock based compensation $ 16,200,000    
Clinigence Holdings, Inc.      
Share-Based Payment Arrangement      
Conversion ratio 3.57143%    
Equity Incentive 2022 Plan      
Share-Based Payment Arrangement      
Stock-based compensation expense $ 16,300,000 $ 600,000  
Share-based award vesting period 24 months    
Multiplying factor 10    
Equity Incentive 2022 Plan | Prior to Reverse Stock Split      
Share-Based Payment Arrangement      
Share price (in dollars per share) $ 2.80    
Equity Incentive 2022 Plan | After the reverse stock split      
Share-Based Payment Arrangement      
Share price (in dollars per share) $ 420.00    
Equity Incentive 2023 Plan      
Share-Based Payment Arrangement      
Maximum aggregate number of shares that may be issued (in shares)   73,426 118,563
Equity Incentive 2023 Plan | Prior to Reverse Stock Split      
Share-Based Payment Arrangement      
Maximum aggregate number of shares that may be issued (in shares)   11,013,943